Registration Strip Icon for alerts Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.

FDMT

4D Molecular Therapeutics (FDMT)

4D Molecular Therapeutics Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:FDMT
DatumZeitQuelleÜberschriftSymbolFirma
30/05/202414h00GlobeNewswire Inc.4DMT to Present Interim Data from Aerosolized 4D-710 Phase 1/2 AEROW Clinical Trial for Cystic Fibrosis at 47ᵗʰ European Cystic Fibrosis ConferenceNASDAQ:FDMT4D Molecular Therapeutics Inc
24/05/202422h28Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:FDMT4D Molecular Therapeutics Inc
24/05/202401h12Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:FDMT4D Molecular Therapeutics Inc
24/05/202401h10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:FDMT4D Molecular Therapeutics Inc
21/05/202402h35Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:FDMT4D Molecular Therapeutics Inc
09/05/202422h22Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:FDMT4D Molecular Therapeutics Inc
09/05/202422h05GlobeNewswire Inc.4DMT Reports First Quarter 2024 Financial Results and Operational HighlightsNASDAQ:FDMT4D Molecular Therapeutics Inc
07/05/202414h00GlobeNewswire Inc.4DMT to Participate in Upcoming Investor ConferenceNASDAQ:FDMT4D Molecular Therapeutics Inc
01/05/202414h00GlobeNewswire Inc.4DMT Announces Presentations at ARVO 2024 Annual MeetingNASDAQ:FDMT4D Molecular Therapeutics Inc
28/03/202413h00GlobeNewswire Inc.4DMT Announces Update on Regulatory Interactions and Development Path for 4D-710 for Treatment of Cystic FibrosisNASDAQ:FDMT4D Molecular Therapeutics Inc
04/03/202414h00GlobeNewswire Inc.4DMT to Participate in Upcoming Investor ConferencesNASDAQ:FDMT4D Molecular Therapeutics Inc
01/03/202400h01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:FDMT4D Molecular Therapeutics Inc
29/02/202423h15Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:FDMT4D Molecular Therapeutics Inc
29/02/202422h12Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:FDMT4D Molecular Therapeutics Inc
29/02/202422h05GlobeNewswire Inc.4DMT Reports Full Year 2023 Financial Results and Operational HighlightsNASDAQ:FDMT4D Molecular Therapeutics Inc
21/02/202423h41Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:FDMT4D Molecular Therapeutics Inc
15/02/202402h51Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:FDMT4D Molecular Therapeutics Inc
14/02/202422h37Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:FDMT4D Molecular Therapeutics Inc
14/02/202414h43Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:FDMT4D Molecular Therapeutics Inc
13/02/202403h04Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:FDMT4D Molecular Therapeutics Inc
13/02/202402h22Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:FDMT4D Molecular Therapeutics Inc
12/02/202414h00GlobeNewswire Inc.4DMT Presents Interim Data from 4D-310 INGLAXA Phase 1/2 Clinical Trials for Fabry Disease Cardiomyopathy at WORLDSymposium™ 2024NASDAQ:FDMT4D Molecular Therapeutics Inc
09/02/202422h56Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:FDMT4D Molecular Therapeutics Inc
08/02/202422h50Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:FDMT4D Molecular Therapeutics Inc
08/02/202422h23Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:FDMT4D Molecular Therapeutics Inc
08/02/202422h22Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:FDMT4D Molecular Therapeutics Inc
08/02/202402h32Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:FDMT4D Molecular Therapeutics Inc
08/02/202401h42Edgar (US Regulatory)Form 3/A - Initial statement of beneficial ownership of securities: [Amend]NASDAQ:FDMT4D Molecular Therapeutics Inc
07/02/202405h27GlobeNewswire Inc.4D Molecular Therapeutics Announces Pricing of Upsized Public Offering of Common StockNASDAQ:FDMT4D Molecular Therapeutics Inc
05/02/202423h27Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:FDMT4D Molecular Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:FDMT

Kürzlich von Ihnen besucht

Delayed Upgrade Clock